MedTrace Logo

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

NCT00891007 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-07-27

No results posted yet for this study

Summary

Partially randomized, controlled Phase II study to evaluate safety, immunogenicity and dose response of the measles vaccine MVA mBN85B in healthy children aged 6 months to 6 years.

Conditions

Interventions

BIOLOGICAL

MVA-mBN85B

Low Dose arm, 1x 10E7 TCID50

BIOLOGICAL

MVA-mBN85B

Normal Dose arm, 1x 10E8 TCID50

BIOLOGICAL

Rouvax

Standard measles vaccine, approved in South Africa

Sponsors & Collaborators

  • Bavarian Nordic

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • South Africa

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891007 on ClinicalTrials.gov